What a week on the obesity battlefield. Listen as Kerry and Luisa dissect the contrasting 2026 guidance from Novo Nordisk and Eli Lilly, the Hims’ obesity pill, TrumpRx, Super Bowl adverts and Clash Royale. The conversation also captures the latest updates on the “Battle of the Pills” in multiple sclerosis for Roche vs Novartis. 

Results season is upon. Listen in for the latest snippets we have picked up plus a summary of our final research reports in January. Our speedy zoom schedule revealed that pharma is investable again. It’s obesity with a larger side-dish of pharma names. Investor sentiment is highest on AstraZeneca, Merck & Co & UCB and lowest on Sanofi, AbbVie and Zealand.

We review our first research notes of 2026 and summarise investor sentiment on large pharma after our annual January 50@50 (speedy zooms). We have termed 2026 “The Battle of the Pills”. Great news for patients – not just in obesity but also breast cancer, lung cancer, multiple sclerosis, cardiomyopathy, hypertension, cholesterolaemia, atopic dermatitis & beyond.